Clinical application progress of PSMA PET in differentiated thyroid cancer

VernacularTitle:PSMA PET在分化型甲状腺癌中的临床应用进展
Author: Enbi ZHANG ¹ ; Wanchun ZHANG
Author Information

1. 山西医科大学医学影像学院，太原　030001
Keywords: Thyroid neoplasms; Prostate-specific membrane antigen; Positron-emission tomography; Trends
From: Chinese Journal of Nuclear Medicine and Molecular Imaging 2024;44(5):313-316
CountryChina
Language:Chinese
Abstract: Differentiated thyroid cancer (DTC) is one of the common endocrine tumors, and the vast majority of DTC have a good prognosis. Some medium- and high-risk patients with DTC may have decreased iodine uptake or progression in spite of maintaining iodine uptake in the natural course of disease or during treatment. 18F-FDG PET/CT is of high significance in detecting recurrent or metastatic lesions in such patients, but there is also a possibility of false negative result. Tumor neovascularization plays an important role in the process of tumor metastasis and invasion. Prostate specific membrane antigen (PSMA) is also expressed in DTC neovascularization, suggesting that PSMA PET has potential value in thyroid cancer. This article reviews the clinical application progress of PSMA PET in DTC.